Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy

Publication date: Available online 13 December 2019Source: Regulatory Toxicology and PharmacologyAuthor(s): Valnês S. Rodrigues-Junior, Anne D. Villela, Bruno L. Abbadi, Nathalia D.M. Sperotto, Kenia Pissinate, Jaqueline N. Picada, Juliana Bondan da Silva, Cristiano V. Bizarro, Pablo Machado, Luiz A. BassoAbstractNew effective compounds to treat tuberculosis are urgently needed. IQG-607 is an orally active anti-tuberculosis drug candidate, with promising preliminary safety profile and anti-mycobacterial activity in both in vitro and in vivo models of tuberculosis infection. Here, we evaluated the mutagenic and genotoxic effects of IQG-607, and its interactions with CYP450 isoforms. Moreover, we describe for the first time a combination study of IQG-607 in Mycobacterium tuberculosis-infected mice. Importantly, IQG-607 had additive effects when combined with the first-line anti-tuberculosis drugs rifampin and pyrazinamide in mice. IQG-607 presented weak to moderate inhibitory potential against CYP450 isoforms 3A4, 1A2, 2C9, 2C19, 2D6, and 2E1. The Salmonella mutagenicity test revealed that IQG-607 induced base pair substitution mutations in the strains TA100 and TA1535. However, in the presence of human metabolic S9 fraction, no mutagenic effect was detected in any strain. Additionally, IQG-607 did not increase micronucleus frequencies in mice, at any dose tested, 25, 100, or 250 mg/kg. The favorable activity in combination with first-line drugs and mild to moderate toxic ev...
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research